ARTESiA: Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation
EP Europace
Lamy A, Sandhu RK, Tong W, McIntyre WF, Lopes RD, Granger CB, Wright DJ, Nielsen JC, Kutyifa V, Erath JW, Alings M, Birnie DH, Atar D, Hohnloser SH, Linde C, Kautzner J, Benezet-Mazuecos J, Camm AJ, Sticherling C, Gold MR, Larroudé CE, Healey JS.
August 2025
